top of page
PRESS
Recardio at ESC Congress 2026
Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced that it is attending the ESC Congress 2026 in Munich.
Jul 291 min read
Recardio at BIO International Convention 2026
Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced that it is participating in the BIO International Convention 2026 in San Diego.
May 261 min read
Recardio Announces Expansion of Series C Financing and Initial Closing of Series C+ Round
Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced the expansion of its Series C financing and the initial close of its Series C+ financing round.
May 61 min read
bottom of page